Indegene Limited (INDGN)
Analysts/Institutional Investor Meet/Con. Call Updates
AI summary
- Q2 FY27 revenue INR11,223 million +39.5% y-y, EBITDA margin 16.7%, PAT margin 10%
- Industry tailwinds: capital up 85% y-y, record drug approvals, larger complex pipeline
- 9 deal wins including $5m+ and $3-5m deals; Tectonic model expanding to Canada
- BioPharm acquisition integration progressing; $1.5m cost synergies reinvested
- Outcome-based contracts growing; $10m+ deal ramping in Q4 impacting margins
- EBITDA margin expected 19%+ by Q4; wage hikes absorbed, productivity gains ongoing
- Largest client revenue stable; top 20 accounts grew 6.7% sequentially
- AI-led Agentic AOR and Tectonic driving upstream growth and new business
- Multiple analyst queries on Tectonic ramp-up, outcome-based revenue, and AI strategy
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 INDGN — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add INDGN to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Indegene Limited
Important.
The summary above is generated automatically from Indegene Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.